A 10-year follow-up of the Norwegian ARCTIC trial offers rare long-term evidence for the treat-to-target approach in rheumatoid arthritis. Among 179 of 218 surviving participants who returned for evaluation, 82% met strict clinical remission criteria, defined as a Disease Activity Score below 1.6. Radiographic joint damage progressed only modestly, with a median change of 2.0 points on the modified van der Heijde-Sharp score, from a baseline average of 0.5.
Early response mattered: participants who had reached remission by year 2 were significantly more likely to still be in remission at year 10 (89.9%) than those who had not (73.1%). Most patients remained on active treatment after a decade, though 15% had stopped all disease-modifying drugs. The study had no non-treat-to-target control group, and patients were not managed according to a fixed protocol between years 2 and 10, so the authors caution that treatments during that gap may have influenced outcomes.
The findings support current recommendations that initial RA treatment should aim for clinical remission, and they offer reassurance that remission, preserved function, and favorable long-term survival are realistic goals for newly diagnosed patients.